Medications for Fabry Disease
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Fabry Disease.
Found 3 Approved Drugs for Fabry Disease
Fabrazyme
Generic Name
Agalsidase
Fabrazyme
Generic Name
Agalsidase
Form: Injection
Method of administration: Intravenous
FDA approval date: December 17, 2008
Classification: Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme
Fabrazyme ® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease. Fabrazyme is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease. ( 1 )
Galafold
Generic Name
Migalastat
Galafold
Generic Name
Migalastat
Form: Capsule
Method of administration: Oral
FDA approval date: August 10, 2018
GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ( GLA ) variant based on in vitro assay data [see Dosage and Administration.
Elfabrio
Generic Name
Pegunigalsidase
Elfabrio
Generic Name
Pegunigalsidase
Form: Injection
Method of administration: Intravenous
FDA approval date: May 23, 2023
ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease. ELFABRIO is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adults with confirmed Fabry disease. ( 1 )
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances